Published in J Surg Oncol on May 01, 2011
Protective effects of matrix metalloproteinase-12 following corneal injury. J Cell Sci (2013) 1.17
Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival. Invest Ophthalmol Vis Sci (2011) 1.08
Novel characterization of lymphatic valve formation during corneal inflammation. PLoS One (2011) 1.00
Live imaging of newly formed lymphatic vessels in the cornea. Cell Res (2011) 0.88
Corneal lymphatic valve formation in relation to lymphangiogenesis. Invest Ophthalmol Vis Sci (2014) 0.84
Increased lymphangiogenesis and hemangiogenesis in infant cornea. Lymphat Res Biol (2011) 0.82
Watching lymphatic vessels grow by making them glow. Cell Res (2011) 0.81
Intravital Imaging Reveals Dynamics of Lymphangiogenesis and Valvulogenesis. Sci Rep (2016) 0.78
Walking the Line: A Fibronectin Fiber-Guided Assay to Probe Early Steps of (Lymph)angiogenesis. PLoS One (2015) 0.77
Conjunctival lymphatic response to corneal inflammation in mice. J Ophthalmol (2012) 0.75
Modeling pre-metastatic lymphvascular niche in the mouse ear sponge assay. Sci Rep (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev (2003) 11.29
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg (1994) 8.85
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
Lymphangiogenesis in development and human disease. Nature (2005) 5.93
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
A combined PET/CT scanner for clinical oncology. J Nucl Med (2000) 4.99
Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science (2009) 4.67
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst (1974) 4.05
Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science (2010) 3.62
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science (1987) 3.44
A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A (2000) 3.28
The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol (2007) 3.20
The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev (2002) 2.99
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med (2004) 2.89
Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med (2007) 2.83
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med (2004) 2.64
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med (2006) 2.27
Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther (1999) 2.21
Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea (2003) 2.00
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med (2002) 1.86
The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med (2003) 1.86
Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A (2001) 1.85
Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med (2002) 1.79
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
The mouse cornea micropocket angiogenesis assay. Nat Protoc (2007) 1.74
Focus on lymphangiogenesis in tumor metastasis. Cancer Cell (2005) 1.74
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.72
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci (2001) 1.71
Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology (2001) 1.67
Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer (2002) 1.67
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther (2008) 1.67
Molecular-genetic imaging based on reporter gene expression. J Nucl Med (2008) 1.64
Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther (2009) 1.61
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate (2005) 1.56
Ocular lymphatics: state-of-the-art review. Lymphology (2009) 1.52
Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol (2007) 1.41
The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med (2003) 1.39
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med (2008) 1.38
Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res (2008) 1.38
Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol (2003) 1.32
Lymphatic system: unlocking the drains. Nature (2005) 1.31
Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer (2007) 1.30
Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther (2002) 1.28
Lymphangiogenesis new mechanisms. Ann N Y Acad Sci (2002) 1.23
Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci (2005) 1.22
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol (2006) 1.20
Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther (2006) 1.17
Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch Ophthalmol (2007) 1.17
Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci (2009) 1.17
Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging (2005) 1.17
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res (2004) 1.13
Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther (2004) 1.10
Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol (2005) 1.09
Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategy. Gene Ther (2010) 1.05
Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res (2000) 1.04
Prognostic significance of lymph nodal metastases in prostate cancer. J Urol (1989) 1.03
Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther (2008) 1.02
Mechanism of colloidal particle uptake into the lymphatic system: basic study with percutaneous lymphography. Radiology (1995) 1.02
A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin Cancer Res (2009) 1.02
Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol Imaging (2005) 1.01
Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum Gene Ther (2000) 0.97
Development of new lymphatic vessels in alkali-burned corneas. Acta Ophthalmol (2008) 0.95
Non-invasive gamma camera imaging of gene transfer using an adenoviral vector encoding an epitope-tagged receptor as a reporter. Gene Ther (2003) 0.95
Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res (2005) 0.93
Genes tell lymphatics to sprout or not. Nat Immunol (2004) 0.93
Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. Gene Ther (2008) 0.92
Limbal lymphangiogenesis after corneal injury: an autoradiographic study. Curr Eye Res (1989) 0.89
Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol (1996) 0.89
Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88
Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther (2004) 0.86
The corneal pocket assay. Methods Mol Biol (2009) 0.86
A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther (2004) 0.86
Endothelial cell lined lymphatics in the vascularized rabbit cornea. Invest Ophthalmol (1966) 0.84
Size- and surface-dependent uptake of colloid particles into the lymphatic system. Lymphology (1999) 0.83
Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther (2002) 0.78
Molecular imaging of reporter gene expression in prostate cancer: an overview. Semin Nucl Med (2008) 0.77
Ultrastructure of lymphatic vessels in the vascularized rabbit cornea. Exp Eye Res (1970) 0.77
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science (2010) 3.62
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood (2009) 2.26
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res (2013) 2.19
A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol (2009) 1.94
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med (2005) 1.93
Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl) (2011) 1.87
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med (2002) 1.86
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res (2005) 1.64
ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J (2006) 1.59
Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res (2002) 1.50
Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci U S A (2009) 1.43
Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med (2008) 1.38
Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res (2008) 1.38
Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A (2009) 1.37
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett (2008) 1.34
Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer (2007) 1.30
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther (2002) 1.28
Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res (2003) 1.27
Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res (2009) 1.27
Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood (2012) 1.24
Domains on the hepatitis C virus internal ribosome entry site for 40s subunit binding. RNA (2002) 1.22
Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther (2006) 1.17
Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate (2010) 1.14
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res (2009) 1.14
The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-mediated degradation in response to death stimuli: identification of a degradation-resistant mutant. J Biol Chem (2006) 1.05
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol (2007) 1.04
Positron-emission tomography reporter gene expression imaging in rat myocardium. Circulation (2003) 1.03
Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther (2004) 1.03
A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials (2010) 1.02
Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther (2008) 1.02
A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin Cancer Res (2009) 1.02
Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol Imaging (2005) 1.01
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther (2004) 0.98
Management of cervical intraepithelial neoplasia 2 in adolescent and young women. J Pediatr Adolesc Gynecol (2007) 0.98
Applications of molecular imaging in cancer gene therapy. Curr Gene Ther (2005) 0.97
Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol (2009) 0.96
Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice. Physiol Genomics (2006) 0.94
Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther (2003) 0.94
Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res (2005) 0.93
Model of the trimeric fiber and its interactions with the pentameric penton base of human adenovirus by cryo-electron microscopy. J Mol Biol (2010) 0.93
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging (2007) 0.92
Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release (2009) 0.92
Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res (2013) 0.91
Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. Endocrinology (2013) 0.90
A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res (2010) 0.90
Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88
Non-invasive molecular imaging of prostate cancer lymph node metastasis. Trends Mol Med (2009) 0.88
Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res (2011) 0.87
In vivo imaging of intraprostatic-specific gene transcription by PET. J Nucl Med (2011) 0.87
Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol (2006) 0.86
Bioluminescence imaging of systemic tumor targeting using a prostate-specific lentiviral vector. Hum Gene Ther (2006) 0.85
Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. J Neurosurg (2013) 0.84
Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther (2002) 0.84
Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol Cancer Ther (2005) 0.83
Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol (2004) 0.83
Reporter gene imaging following percutaneous delivery in swine moving toward clinical applications. J Am Coll Cardiol (2008) 0.83
Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther (2013) 0.83
A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo. Mol Ther (2012) 0.82
Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels. Mol Genet Metab (2010) 0.82
Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system. Future Oncol (2006) 0.81
Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor. J Nucl Med (2009) 0.80
Maternal risk factors for neonatal necrotizing enterocolitis. J Matern Fetal Neonatal Med (2014) 0.80
Imaging mitogen-activated protein kinase function in xenograft models of prostate cancer. Cancer Res (2006) 0.77
Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes. Prostate (2005) 0.77
A dual-targeted lentiviral vector homing in on prostate bone metastases. Mol Ther (2007) 0.77
Engineering polypeptide coatings to augment gene transduction and in vivo stability of adenoviruses. J Control Release (2012) 0.77
Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts. PLoS One (2013) 0.77
Cardiac glycosides may affect prostate specific antigen levels. J Urol (2010) 0.75
Chapter five--The development of transcription-regulated adenoviral vectors with high cancer-selective imaging capabilities. Adv Cancer Res (2012) 0.75
Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. Sci Rep (2016) 0.75